Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.

PURPOSE To study the main clinicobiologic features, response, and outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to the primary site, lymph node, or different extranodal organs of the disease. PATIENTS AND METHODS We included 382 patients consecutively diagnosed with DLBCL in a single institution during a 13-year period. Morphology, immunophenotyping, proliferation index, differentiation profile, bcl-2/JH rearrangement, and clinical characteristics were analyzed according to the primary site of the lymphoma. RESULTS Sites of the disease were: lymph node, 222 cases (58%); Waldeyer's ring (WR), 42 (11%); and extranodal sites, 118 (31%), including GI tract in 45 cases. Primary extranodal cases, particularly GI, showed a bcl-6 expression more frequently than nodal cases. Patients with primary WR or GI lymphomas presented with early-stage disease, no marrow infiltration, normal serum lactate dehydrogenase, and low- to low/intermediate-risk international prognostic index (IPI) more frequently than the remainder. Complete response (CR) rate was 63%, with WR and GI lymphomas having a higher CR rate (85% and 80%, respectively) than the other groups. In the whole series, 5-year overall survival (OS) was 52%. Patients with WR or GI lymphomas showed better OS (5-year OS: 77% and 68%, respectively) than patients with nodal or other extranodal sites. In the multivariate analysis, IPI, bulky disease, and beta2-microglobulin were the main variables to predict OS; no nodal or extranodal site maintained their prognostic value. CONCLUSION In the present series, the primary site of disease was associated with particular clinicopathologic features and outcome, though the latter largely depended on other factors.

[1]  W. Grody,et al.  36 – Diffuse Large B-Cell Lymphoma , 2006 .

[2]  A. López-Guillermo,et al.  Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[4]  A. Chott,et al.  FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. , 2004, The American journal of pathology.

[5]  Nallasivam Palanisamy,et al.  Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. , 2004, Blood.

[6]  Ramón Bosch,et al.  Building an outcome predictor model for diffuse large B-cell lymphoma. , 2004, The American journal of pathology.

[7]  B. Christensen,et al.  Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.

[8]  S. Cessie,et al.  Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Emili Montserrat,et al.  Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.

[10]  B. Falini,et al.  Diffuse large B‐cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification , 2002, Histopathology.

[11]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[12]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[13]  S. Devesa,et al.  Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. , 2000, Journal of the National Cancer Institute.

[14]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[15]  Clara D. Bloomfield,et al.  The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. , 2000, The hematology journal : the official journal of the European Haematology Association.

[16]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  F. Cavalli,et al.  Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[19]  P. Guldberg,et al.  Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. , 1998, Blood.

[20]  J. Cigudosa,et al.  Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.

[21]  V. Beral,et al.  The epidemiology of non‐Hodgkin's lymphoma: Comparison of nodal and extra‐nodal sites , 1997, International journal of cancer.

[22]  F. Cavalli,et al.  Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[24]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[25]  H. Ohno,et al.  Rearrangement of the BCL6 gene in B‐cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement , 1996, British journal of haematology.

[26]  K. Offit,et al.  REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma , 1996 .

[27]  Sutcliffe,et al.  The Extranodal Lymphomas. , 1995, Seminars in radiation oncology.

[28]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[29]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[30]  F. d'Amore,et al.  Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas , 1991 .

[31]  R. Willemze,et al.  Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. , 1989, European journal of cancer & clinical oncology.

[32]  M. Ross,et al.  Primary extranodal lymphoma. Response to treatment and factors influencing prognosis , 1978, Cancer.

[33]  M. Pike,et al.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. , 1973, Biometrics.

[34]  J. Berg,et al.  Occurrence and prognosis of extranodal lymphomas , 1972 .

[35]  D. Cox Regression Models and Life-Tables , 1972 .

[36]  I. Dawson,et al.  Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis , 1961, The British journal of surgery.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .